期刊文献+

Quinoline Ring Derivatives as Potent Integrase Inhibitors Using Ligand-based Modeling Studies

Quinoline Ring Derivatives as Potent Integrase Inhibitors Using Ligand-based Modeling Studies
原文传递
导出
摘要 Integrase has become an attractive target for the design of anti-HIV inhibitor because it plays a quite important role in the process of HIV-1 virus replication. The quinoline ring derivatives, which have the similar pharmacophore toβ-diketoacids, are the kind of integrase inhibitor with highly antiviral activity. A series of quinoline ring derivatives were analyzed by the comparative molecular field analysis(Co MFA), comparative molecular similarity induces analysis(Co MSIA) and Topomer Co MFA methods. Firstly, we chose 77 compounds from former papers as a dataset,followed by dividing it into the training set and test set randomly. Then, we constructed predictive models of Co MFA, Co MSIA and Topomer Co MFA, respectively. The Co MFA yielded the best cross-validated model with a q2=0.758, non-cross-validated r2=0.988.The Co MSIA model yielded a q2=0.701 and r2=0.986 while the Topomer Co MFA model has q2=0.661 and r2=0.966. Through verification, these results suggested a strong predictive ability to the design of novel highly active HIV-1 integrase inhibitors for therapy. Integrase has become an attractive target for the design of anti-HIV inhibitor because it plays a quite important role in the process of HIV-1 virus replication. The quinoline ring derivatives, which have the similar pharmacophore to ^-diketoaeids, are the kind of integrase inhibitor with highly antiviral activity. A series of quinoline ring derivatives were analyzed by the comparative molecular field analysis (CoMFA), comparative molecular similarity induces analysis (CoMSIA) and Topomer CoMFA methods. Firstly, we chose 77 compounds from former papers as a dataset, followed by dividing it into the training set and test set randomly. Then, we constructed predictive models of CoMFA, CoMSIA and Topomer CoMFA, respectively. The CoMFA yielded the best cross-validated model with a q2=0.758, non-cross-validated r2=0.988. The CoMSIA model yielded a q2=0.701 and r^2=0.986 while the Topomer CoMFA model has q2=0.661 and r2=0.966. Through verification, these results suggested a strong predictive ability to the design of novel highly active HIV-1 integrase inhibitors for therapy.
出处 《Chinese Journal of Biomedical Engineering(English Edition)》 CSCD 2015年第1期33-39,共7页 中国生物医学工程学报(英文版)
关键词 computer-aided drug design 3D-QSAR HIV-1 integrase inhibitor Co MFA Co MSIA Topomer Co MFA computer-aided drug design 3D-QSAR HIV-1 integrase inhibitor CoMFA CoMSIA Topomer CoMFA
  • 相关文献

参考文献18

  • 1Leonard JT, Roy K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors [J]. European Journal of Medicinal Chemistry, 2008,43(1):81-92.
  • 2Tan JJ, Cong XJ, Hu LM, et al. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infeetion[J]. Drug Discovery Today, 2010,15(5-6):186-197.
  • 3Sharer RW, nitton DA. Highly active antiretroviral therapy (HAART) for the treatment of infeetion with human innnunodeficieney virus type 1 [J].Biomedicine & Pharmaeotherapy, 1999,53(2):73-86.
  • 4Este JA, Cihlar T. Current status and challenges of antiretroviral research and therapy [J]. Antiviral Research, 2010,85(1):25-33.
  • 5Ray S, Fatima Z, Saxena A. Drugs for AIDS [J]. Mini Reviews in Medicinal ChemistT, 2010,10(2):147-161.
  • 6Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration [J]. Brazilian Journal of Intctious Diseases, 2010,14(5):513-518.
  • 7Powderly WG. Integrase inhibitors in the treatment of HI V-1 infection [J]. The Journal of Antimierobial Chemotherapy, 2010,65:2485-2488.
  • 8Gatell JM, Katlama C, Grinsztejn B, et al.Long-ternl efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study [J]. Journal of Acquired Immune Deficiency Syndrome, 2010,53(4):456-463.
  • 9Mouscadet JF, Delelis O, Marcelin AG. Tchertanov, resistance [J]. Drug Resistance Updates, 2010, 13(4-5): 139-150. integrase inhibitors: A structural perspective.
  • 10Chiu TK, Davies DR. Structure and fimction of HIV-1 integn-ase [J]. Current Topics in Medicinal Chemistry,2004, 4 (9):965-977.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部